Nipro exit from troubled Bipha JV may smooth Mitsubishi Tanabe blood product rejig
This article was originally published in Scrip
The Japanese blood product operation Bipha will once again become a wholly owned subsidiary of Mitsubishi Tanabe Pharma (MTP) following a decision by long-time partner Nipro Corp to divest its interest in the joint venture.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context